Saturday 17 October 2026
Export CHE’s income statement to Excel — free account
Chemed Corporation
CHE Healthcare Medical Care Facilities
Chemed Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 4.06% from fiscal 2024. In the quarter to June 2026, revenue grew 8.80%, EPS grew 42.8% and free cash flow fell 43.5%, each against the same quarter a year earlier. Dividend growth for twenty-five consecutive years, revenue growth for three.
512.38
3.06
−0.59%
Follow CHE
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
23.37 | 20.54 | 23.19 | 23.50 |
+8 more quarters Free account |
P/S ratio |
2.36 | 2.03 | 2.43 | 2.55 | |
P/FCF ratio |
18.70 | 13.53 | 18.67 | 17.68 | |
P/Operating CF |
72.34 | 58.55 | 46.13 | 77.29 | |
P/B ratio |
7.39 | 6.09 | 6.29 | 5.99 | |
Price to Tangible BV |
116.84 | 64.51 | 26.83 | 19.84 | |
EV/Sales |
2.40 | 2.06 | 2.45 | 2.54 | |
EV/EBITDA |
15.00 | 13.31 | 15.34 | 15.43 | |
EV/Operating CF |
16.00 | 11.82 | 15.94 | 15.30 | |
EV/FCF |
19.02 | 13.74 | 18.75 | 17.61 | |
Quick Ratio |
0.72 | 0.72 | 0.90 | 1.18 | |
Current Ratio |
0.91 | 0.85 | 1.05 | 1.35 | |
Net Debt/EBITDA |
0.94 | 0.73 | (0.64) | (1.42) | |
Debt/Assets |
8.86% | 5.94% | 0.00% | 0.00% | |
Debt/Equity |
0.17 | 0.11 | 0.00 | 0.00 | |
Asset Turnover |
1.57 | 1.56 | 1.58 | 1.49 | |
Operating CF/Net income |
1.25 | 1.33 | 1.74 | 1.30 | |
Capex/Depreciation |
(0.89) | (1.00) | (0.95) | (0.86) | |
Interest Coverage |
49.86 | 165.19 | 193.19 | 163.57 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
17.11% | 17.39% | 16.50% | 16.93% | |
Intangible Assets out of Total Assets |
0.49 | 0.50 | 0.49 | 0.46 | |
Share Based Compensation of Revenue |
1.68% | 1.62% | 1.58% | 0.94% | |
Graham Net Nets |
(0.07) | (0.08) | (0.04) | (0.02) | |
Graham Number |
168.14 | 160.18 | 168.04 | 179.06 | |
Earnings Yield |
4.28% | 4.87% | 4.31% | 4.25% | |
Free Cash Flow Yield |
5.35% | 7.39% | 5.36% | 5.65% | |
Revenue per Share |
51.10 | 48.08 | 44.40 | 43.41 | |
Operating CF per Share |
6.44 | 6.45 | 9.27 | 5.79 | |
Capex per Share |
(1.16) | (1.24) | (1.08) | (0.98) | |
Free Cash Flow per Share |
5.28 | 5.21 | 8.20 | 4.81 | |
Cash per Share |
3.05 | 1.23 | 5.18 | 9.01 | |
Shareholders Equity per Share |
63.04 | 62.01 | 68.02 | 74.80 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
63.04 | 62.01 | 68.02 | 74.80 | |
Free Cash Flow |
69.58 | 71.24 | 118.00 | 69.30 | |
Working Capital |
(28.61) | (47.35) | 15.49 | 103.20 | |
Capital Expenditures |
(15.23) | (16.98) | (15.53) | (14.09) | |
Net Current Asset Value |
(457.84) | (413.76) | (256.17) | (151.69) | |
EV/EBIT |
17.87 | 15.99 | 18.30 | 18.26 | |
Capex to Sales |
0.02 | 0.03 | 0.02 | 0.02 | |
Price to Operating Income |
17.57 | 15.75 | 18.21 | 18.34 | |
| Other line items | |||||
Average Receivables |
186.76 | 250.68 | 176.87 | 206.03 | |
Average Payables |
67.79 | 56.70 | 54.30 | 46.52 | |
Average Inventory |
8.39 | 7.50 | 7.87 | 9.07 | |
Average Assets |
1,648.72 | 1,631.17 | 1,603.38 | 1,696.53 | |
Average Common Equity |
1,014.50 | 1,014.88 | 1,049.20 | 1,156.22 |
Columns are period end dates